Document is current
Any future updates will be listed below
-
Authors
Westwood, Alice C.
Wilson, Benjamin I.
Laye, Jon
Grabsch, Heike I.
Mueller, Wolfram
Magee, Derek R.
Quirke, Phillip
West, Nicholas P.
-
Funding
Funding for this research was provided by:
Cancer Research UK (S4154)
Cancer Research UK (RRCOER-Jun24/100004)
UK Research and Innovation (EP/S024336/1)
NIHR (NIHR203331)
NIHR (NIHR203331)
NIHR (NIHR203331)
NIHR (NIHR203331)
NIHR (NIHR203331)
Yorkshire Cancer Research (L386)
Yorkshire Cancer Research (L386)
- License Information
-
More Information
Article History
Received: 23 September 2024
Revised: 20 December 2024
Accepted: 17 January 2025
First Online: 3 March 2025
Competing interest
: HG received honoraria from Astra Zeneca and Bristol Myers Squibb not related to the study. NW has undertaken paid consultancy for Bristol Myers Squibb, GSK, Astellas, Pfizer and Amgen not related to this study. PQ declares research funding from Roche and honoraria for lectures by Roche, Bayer, Amgen, not related to the study. DM is director and shareholder of HeteroGenius Limited. AW received honoraria from Servier not related to this study.
: Ethical approval for the study was provided by North East – York Research Ethics Committee (ref. 08/H0903/62). The study was performed in accordance with local ethics regulation, the need for individual patient consent was waived by the ethics committee. The study was conducted in compliance with the Declaration of Helsinki.
